Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Does maintenance of Bevacizumab after treatment failure have a role in metastatic colon cancer?
Chinese-German Journal of Clinical Oncology, Volume 8, No. 1, Year 2009
Notification
URL copied to clipboard!
Description
Objective: To study the timing of Bevacizumab (BVC) in the overall treatment strategy of advanced metastatic colorectal cancer - early use (first-line) or later use. Methods: 41 patients with progressive metastatic colorectal carcinoma were included. Patients were randomized to receive chemotherapy with or without BVC. Primary end point was objective response. Secondary end points were median survival, time to tumor progression, and toxicity. Results: Partial response with second-line BVC group constituted 25% and 18.8% in patients with first-line chemotherapy and BVC-based regimen respectively, compared to 11.8% and 5.9% with second-line chemotherapy. Median time to progression was 3.1 vs. 2.3 months for cases with first-line chemotherapy and BVC-based regimens respectively. Median survival was 8.2 vs. 4 months in both groups respectively (P = 0.019). Conclusion: Second-line chemotherapy combined BVC had higher disease control rate (partial response and stable disease), median time to progression and median survival in BVC-naïve patients compared to patients with first-line BVC-based therapy. BVC should be maintained in the second- and third-line settings, as cases with BVC discontinuation had significantly lower median time to disease progression and median survival. Selection of patients for use of BVC was recommended with taking into consideration the cost-benefit value and that the discontinuation of BVC would increase tumor progression. © Springer-Verlag Berlin Heidelberg 2009.
Authors & Co-Authors
Galal, Khaled Morsi
Egypt, Giza
Cairo University
Saudi Arabia, Jeddah
Saudi German Hospital
Zaghlol, Khaled
Egypt, Tanta
Tanta University
Fawzy, Ehab Esmat
Egypt, Giza
Cairo University
Saudi Arabia, Jeddah
King Abdulaziz University Hospital Kauh
Mansour, S.
Saudi Arabia, Jeddah
Saudi German Hospital
Egypt, Mansoura
Faculty of Medicine
Salam, Mahmoud Abdul
Egypt, Giza
Cairo University
Saudi Arabia, Riyadh
King Faisal Specialist Hospital and Research Centre
Mohamed, E. M.
Saudi Arabia, Jeddah
Saudi German Hospital
Egypt, Cairo
Ain Shams University
Statistics
Citations: 6
Authors: 6
Affiliations: 7
Identifiers
Doi:
10.1007/s10330-007-0168-3
ISSN:
16101979
e-ISSN:
16139089
Research Areas
Cancer